A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the effect of FTY720 on the lung function of patients with moderate asthma

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Fingolimod Hydrochloride

Criteria

Inclusion Criteria:

• Forced Expiratory Volume in 1 second of at least 60%

• History of asthma for at least 6 months

• Current use of short-acting beta agonists, inhaled long-acting beta agonists and inhaled corticosteroids (up to a specified dose)

Exclusion Criteria:

• History of lung disease other than asthma

• Smokers

• Use of inhaled corticosteroid above specified dose

• Use of oral beta agonists or corticosteroids or other asthma medications

• Hypersensitivity to the drug

• Respiratory tract infections within 1 month of the study

Other protocol-defined inclusion/exclusion criteria may apply